Business
US-SPACE-BOEING-STARLINER-AEROSPACE
The United Launch Alliance Atlas V rocket with Boeing's CST-100 Starliner spacecraft (Miguel J. Rodriguez Carrillo/Getty Images)

Boeing is really bad at lots of very complicated things

That means it’s really good at losing money. Now it’s raising tens of billions of dollars and trying to sell its space operations.

A couple weeks ago on the Snacks Mix podcast, we contrasted Boeing’s recent miscues with SpaceX’s recent successes.

Boeing just posted a $6 billion quarterly loss (its second-largest quarterly loss on record), it is losing $50 million per day while its factory workers are still on strike, it made plans to lay off 10% of its workforce, it has $60 billion in debt, it had to raise $21 billion in a stock issuance to stave off a credit downgrade, and after years of PR crises thanks to its Boeing 737 MAX issues, Boeing left two astronauts stranded at the International Space Station after NASA deemed thruster failure and helium leaks on Boeing’s Starliner too risky to make the return trip with astronauts onboard.

Now, SpaceX, which just caught a 232-foot rocket booster with a set of “chopsticks” built into its launch facility, is handling the astronauts’ rescue mission in February.

As if things couldn’t get any worse, The Wall Street Journal reported Friday that Boeing is exploring a sale of its space business, which includes its Starliner spacecraft, as part of new CEO Kelly Ortberg’s plan to cut back the company’s financial losses. As noted above, Boeing lost $6 billion last quarter, and it’s currently losing $50 million a day as this strike drags on.

A big portion of that loss stems from the company’s Defense, Space & Security segment. This segment, which includes Boeing’s space program, lost $2.4 billion on $5.5 billion in revenue in Q3 this year, including a $250 million charge reflecting “schedule delays and higher testing and certification costs.”

News of this potential sale comes two months after Reuters reported that Boeing and Lockheed Martin want to sell the United Launch Alliance, their joint-venture launch provider that launched Boeing’s Starliner mission to the ISS in June. Given Boeing’s precarious financial situation (high debt load, mounting losses, etc.) and uncertainty surrounding its space business following the recent issues with its Starliner spacecraft, it makes sense for the company to focus on its core business of plane manufacturing, which has been dealing with its own problems. With Boeing’s former CEO stating in 2022 that Boeing had no plans for a new plane until the mid-2030s, and the company’s factory workers still costing it $50 million per day while they strike, one has to wonder when the bad news for Boeing will finally end.

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Texas Governor Abbott And Google Make Economic Development Announcement In Midlothian

Alphabet could buy some pretty huge businesses with the amount of money it plans to spend this year

AI outlays have gone full nut-nut. Even Google, one of the most capital-efficient businesses of all time in its heyday, is spending like there’s no tomorrow.

Tom Jones2/6/26

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.